RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+23.39%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$1.47B
AUM Growth
+$1.47B
(+35%)
Cap. Flow
+$154M
Cap. Flow
% of AUM
10.53%
Top 10 Holdings %
Top 10 Hldgs %
58.22%
Holding
54
New
7
Increased
25
Reduced
10
Closed
4
Top Buys
| 1 |
ProQR Therapeutics
PRQR
|
$45.4M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$37M |
| 3 |
Bristol-Myers Squibb
BMY
|
$27.4M |
| 4 |
PTC Therapeutics
PTCT
|
$22.3M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$21.4M |
Top Sells
| 1 |
Arrowhead Research
ARWR
|
$69.5M |
| 2 |
Regenxbio
RGNX
|
$34.3M |
| 3 |
uniQure
QURE
|
$18.4M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$15.9M |
| 5 |
Assembly Biosciences
ASMB
|
$15.5M |
Sector Composition
| 1 | Healthcare | 91.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $280M | 19.13% | 16,037,486 | – | – |
|
|
2
PTC Therapeutics
PTCT
$3.92B
| $94.6M | 6.46% | 2,514,271 +591,925 | +31% | +$22.3M |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $91.2M | 6.22% | 6,223,036 +315,948 | +5% | +$4.63M |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $78.1M | 5.33% | 835,873 +396,375 | +90% | +$37M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $72.8M | 4.97% | 1,525,464 +574,684 | +60% | +$27.4M |
|
|
6
ProQR Therapeutics
PRQR
$237M
| $51.6M | 3.52% | 3,722,950 +3,274,809 | +731% | +$45.4M |
|
7
Masimo
MASI
$7.59B
| $50.3M | 3.43% | 363,569 +21,348 | +6% | +$2.95M |
|
8
Q32 Bio
QTTB
$20.9M
| $48.2M | 3.29% | 1,736,719 +103,228 | +6% | +$2.86M |
|
9
Vericel Corp
VCEL
$1.83B
| $43.6M | 2.97% | 2,487,922 +198,788 | +9% | +$3.48M |
|
10
LivaNova
LIVN
$3.08B
| $42.3M | 2.89% | 435,136 -7,900 | -2% | -$768K |
|
|
ACHN
11
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $40.7M | 2.78% | 13,749,383 | – | – |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $40.3M | 2.75% | 338,199 -27,712 | -8% | -$3.3M |
|
|
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $36.7M | 2.51% | 706,570 +411,672 | +140% | +$21.4M |
|
|
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
| $36.5M | 2.49% | 1,524,030 +428,634 | +39% | +$10.3M |
|
15
Adverum Biotechnologies
ADVM
$64.6M
| $32.8M | 2.24% | 6,256,840 | – | – |
|
16
Establishment Labs
ESTA
$1.2B
| $31.9M | 2.18% | 1,325,539 +477,481 | +56% | +$11.5M |
|
|
AGEN
17
Agenus
AGEN
$133M
| $29.4M | 2% | 9,883,213 -251,906 | -2% | -$748K |
|
|
18
Arrowhead Research
ARWR
$3.05B
| $28M | 1.91% | 1,528,213 -3,787,943 | -71% | -$69.5M |
|
|
19
Regenxbio
RGNX
$451M
| $25.9M | 1.77% | 451,182 -599,063 | -57% | -$34.3M |
|
20
Standard BioTools
LAB
$481M
| $25.7M | 1.75% | 1,930,934 +1,046,699 | +118% | +$13.9M |
|
21
SI-BONE Inc
SIBN
$719M
| $23.9M | 1.63% | 1,269,194 +464,867 | +58% | +$8.76M |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22.9M | 1.56% | 312,093 +273,328 | +705% | +$20M |
|
|
CNCE
23
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $20.4M | 1.39% | 1,688,448 +899,571 | +114% | +$10.9M |
|
24
Arbutus Biopharma
ABUS
$711M
| $19.7M | 1.35% | 5,510,223 +1,174,477 | +27% | +$4.2M |
|
25
Apyx Medical
APYX
$75.3M
| $19.7M | 1.35% | 3,124,899 +733,001 | +31% | +$4.63M |
|